A share price of CRISPR Therapeutics AG [CRSP] is currently trading at $57.57, up 3.94%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CRSP shares have gain 2.42% over the last week, with a monthly amount glided 2.90%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
On December 11, 2023, downgrade downgraded it’s rating to Underperform but maintained its price target of $30 on the stock. Cantor Fitzgerald downgraded its rating to a Neutral. Mizuho initiated its recommendation with a Buy and recommended $82 as its price target on September 27, 2023. Citigroup upgraded its rating to Buy for this stock on August 17, 2023. In a note dated May 30, 2023, William Blair initiated an Outperform rating and provided a target price of $75 on this stock.
CRISPR Therapeutics AG experienced fluctuations in its stock price throughout the past year between $37.55 and $91.10. Currently, Wall Street analysts expect the stock to reach $124.64 within the next 12 months. CRISPR Therapeutics AG [NASDAQ: CRSP] shares were valued at $57.57 at the most recent close of the market. An investor can expect a potential return of 116.5% based on the average CRSP price forecast.
Analyzing the CRSP fundamentals
Trailing Twelve Months sales for CRISPR Therapeutics AG [NASDAQ:CRSP] were 271.71M which represents -99.50% decline. Gross Profit Margin for this corporation currently stands at 0.48% with Operating Profit Margin at -1.1%, Pretax Profit Margin comes in at -0.79%, and Net Profit Margin reading is -0.8%. To continue investigating profitability, this company’s Return on Assets is posted at -0.09, Equity is -0.12 and Total Capital is -0.13. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 55.67 points at the first support level, and at 53.76 for the second support level. However, for the 1st resistance point, the stock is sitting at 59.12, and for the 2nd resistance point, it is at 60.66.
Ratios To Look Out For
To put it in perspective, the Current Ratio for CRISPR Therapeutics AG [NASDAQ:CRSP] is 17.81. Also, the Quick Ratio is 17.81, while the Cash Ratio stands at 5.95. Considering the valuation of this stock, the price to sales ratio is 17.99, the price to book ratio is 2.34.
Transactions by insiders
Recent insider trading involved Bruno Julianne, Chief Operating Officer, that happened on Jun 21 ’24 when 3366.0 shares were sold. Chief Executive Officer, Kulkarni Samarth completed a deal on Apr 15 ’24 to sell 19582.0 shares. Meanwhile, Chief Executive Officer Kulkarni Samarth sold 20000.0 shares on Mar 15 ’24.
